PDF
ePub
Citation
Print
Abstract
Opioids are effective analgesics, but they are often difficult to use properly, due mainly to adverse events, such as constipation, respiratory depression, addiction, tolerance, and opioid induced hyperalgesia. In the past, the problem of opioids around the world was usually caused by drugs traded illegally, so there was no need for medical and social attention in Korea. On the other hand, with the dramatic increase in the therapeutic use of opioids, which commenced more than a decade ago, problems caused by legally prescribed drugs have emerged, and now a more serious opioid crisis is being experienced than in the days of illegal drugs. A growing number of patients are chronically prescribed opioids, and a growing number of health care providers and hospitals suffer from problems related to chronic prescription. Currently, in Korea, it is the time to pay serious attention to achieve the safe and effective use of prescribed opioids. This paper consists of the following parts. 1) A summary of the issues related to chronic pain, opioids, and problems associated with the use of opioids. 2) Some case examples the authors' experienced. 3) Simple guidelines on the use of opioids in the treatment of chronic non-cancer pain are proposed based on the author's experience and existing literature. These guidelines are by no means comprehensive, and hopefully in the future, related experts will join forces to develop better guidelines.
Figures and Tables
References
1. Moulin DE, Clark AJ, Speechley M, Morley-Forster PK. Chronic pain in Canada--prevalence, treatment, impact and the role of opioid analgesia. Pain Res Manag. 2002; 7:179–184.
2. Volkow ND, McLellan AT. Opioid abuse in chronic pain--misconceptions and mitigation strategies. N Engl J Med. 2016; 374:1253–1263.
3. Cho YS, Lee JY, Kim HS, Kwon KH. Trends in the consumption of opioid analgesics in a tertiary care hospital from 2000 to 2012. Yakhak Hoeji. 2014; 58:268–276.
4. Kim CJ. A nurse at Seoul National University Hospital tricked her into taking drugs for patients. The Hankook Ilbo. update 2018 Apr 6. cited 2019 Dec 12. Available from: https://www.hankookilbo.com/News/Read/201804060448359697.
5. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006; 10:287–333.
6. Merskey H, Bogduk N. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. 2nd ed. Seattle: IASP Press;1994.
7. Vlaeyen JW, Crombez G, Linton SJ. The fear-avoidance model of pain. Pain. 2016; 157:1588–1589.
8. Merskey H. History and definition of pain. In : Rashiq S, Schopflocher D, Taenzer P, Jonsson E, editors. Chronic pain: a health policy perspective. Hoboken, NJ: Wiley-Blackwell;2008. p. 19–28.
9. Yoon DM. Analgesic therapy according to disease specific pathophysiology. J Korean Med Assoc. 2011; 54:739–746.
10. Lee YW. Opioid therapy for chronic nonmaliganat pain. Hanyang Med Rev. 2011; 31:70–75.
11. Merskey H. The definition of pain. Eur Psychiatry. 1991; 6:153–159.
12. Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull. 2007; 133:581–624.
13. Baron R. Mechanisms of disease: neuropathic pain--a clinical perspective. Nat Clin Pract Neurol. 2006; 2:95–106.
14. D'Costa RAFJ, Hanna M. Opioids, their receptors, and pharmacology. In : Hanna M, Zylicz Z, editors. Cancer pain. London: Springer;2013. p. 109–119.
15. Park SS. Cancer pain management-opioids. J Korean Med Assoc. 2010; 53:250–257.
16. Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol. 2004; 2:395–402.
17. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992; 267:2750–2755.
18. O'Brien CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol. 1996; 13:35–39.
19. Chang HM, Chen LY. Management of chronic pain and opioid dependence with buprenorphine/naloxone. Psychiatry Clin Neurosci. 2018; 72:454.
20. Chen KY, Chen L, Mao J. Buprenorphine-naloxone therapy in pain management. Anesthesiology. 2014; 120:1262–1274.
21. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006; 174:1589–1594.
22. Huxtable CA, Roberts LJ, Somogyi AA, MacIntyre PE. Acute pain management in opioid-tolerant patients: a growing challenge. Anaesth Intensive Care. 2011; 39:804–823.
23. Esfahlan AJ, Lotfi M, Zamanzadeh V, Babapuor J. Burn pain and patients' responses. Burns. 2010; 36:1129–1133.
24. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain--United States, 2016. JAMA. 2016; 315:1624–1645.
25. McQuay H. Relief of chronic non-malignant pain. In : Morris PJ, Wood WC, editors. Oxford textbook of surgery. 2nd ed. NY: Oxford University Press;2000. p. 3521–3532.
26. Sohn KS, Kim JH. Recent trends in pharmacologic treatment of cancer pain. J Korean Med Assoc. 2012; 55:666–675.
27. NCCN, Inc.[homepage on the Internet] Adult cancer pain. Plymouth Meeting. PA: National Comprehensive Cancer Network;c2012. cited 2019 dec 11. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
28. Portenoy RK. Treatment of cancer pain. Lancet. 2011; 377:2236–2247.
29. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010; CD006605.
30. Eriksen J, Sjøgren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. 2006; 125:172–179.
31. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA. 1995; 274:1870–1873.
32. Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015; 162:276–286.
33. Manchikanti L, Ailinani H, Koyyalagunta D, Datta S, Singh V, Eriator I, et al. A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain. Pain Physician. 2011; 14:91–121.
34. Busse JW, Wang L, Kamaleldin M, Craigie S, Riva JJ, Montoya L, et al. Opioids for chronic noncancer pain: a systematic review and metaanalysis. JAMA. 2018; 320:2448–2460.
35. Holzer P, Ahmedzai SH, Niederle N, Leyendecker P, Hopp M, Bosse B, et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag. 2009; 5:145–151.
36. Lötsch J, Dudziak R, Freynhagen R, Marschner J, Geisslinger G. Fatal respiratory depression after multiple intravenous morphine injections. Clin Pharmacokinet. 2006; 45:1051–1060.
37. Calcaterra S, Glanz J, Binswanger IA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009. Drug Alcohol Depend. 2013; 131:263–270.
38. Ladapo JA, Larochelle MR, Chen A, Villalon MM, Vassar S, Huang DYC, et al. Physician prescribing of opioids to patients at increased risk of overdose from benzodiazepine use in the United States. JAMA Psychiatry. 2018; 75:623–630.
39. Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995; 15:49–57.
40. Nyhuis PW, Specka M, Gastpar M. Does the antidepressive response to opiate treatment describe a subtype of depression? Eur Neuropsychopharmacol. 2006; 16:Suppl 4. S309.
41. Miller M, Barber CW, Leatherman S, Fonda J, Hermos JA, Cho K, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med. 2015; 175:608–615.
42. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: APA Publishing;2013.
43. Park SY, Kang UG. What is addiction (I): pathophysiology and therapeutic implications. J Korean Acad Addict Psychiatry. 2014; 18:3–16.
44. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003; 35:253–259.
45. Kosten TR, O’Connor PG. Management of drug and alcohol withdrawal. N Engl J Med. 2003; 348:1786–1795.
46. Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: evidence and recommendations for everyday practice. Mayo Clin Proc. 2015; 90:828–842.
47. Gowing L, Farrell MF, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2014; 1:CD002024.
48. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006; 104:570–587.
49. Sørensen J, Sjøgren P. Opioid-induced hyperalgesia. In : Hanna M, Zylicz Z, editors. Cancer pain. London: Springer-Verlag;2013. p. 131–142.
50. Arout CA, Edens E, Petrakis IL, Sofuoglu M. Targeting opioid-induced hyperalgesia in clinical treatment: neurobiological considerations. CNS Drugs. 2015; 29:465–486.
51. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician. 2008; 11:2 Suppl. S105–S120.
52. Juni A, Klein G, Kest B. Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems. Brain Res. 2006; 1070:35–44.
53. Suzan E, Eisenberg E, Treister R, Haddad M, Pud D. A negative correlation between hyperalgesia and analgesia in patients with chronic radicular pain: is hydromorphone therapy a double-edged sword? Pain Physician. 2013; 16:65–76.
54. Kayan S, Woods LA, Mitchell CL. Morphine-induced hyperalgesia in rats tested on the hot plate. J Pharmacol Exp Ther. 1971; 177:509–513.
55. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011; 152:3 Suppl. S2–S15.
56. Vanderah TW, Ossipov MH, Lai J, Malan TP Jr, Porreca F. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain. 2001; 92:5–9.
57. Vanderah TW, Suenaga NM, Ossipov MH, Malan TP Jr, Lai J, Porreca F. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci. 2001; 21:279–286.
58. Li X, Clark JD. Hyperalgesia during opioid abstinence: mediation by glutamate and substance p. Anesth Analg. 2002; 95:979–984.
59. Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 2003; 26:696–705.
60. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain. 2002; 100:213–217.
61. Ackerman WE 3rd. Paroxysmal opioid-induced pain and hyperalgesia. J Ky Med Assoc. 2006; 104:419–423.
62. Meyer-Rosberg K, Burckhardt CS, Huizar K, Kvarnström A, Nordfors LO, Kristofferson A. A comparison of the SF-36 and Nottingham Health Profile in patients with chronic neuropathic pain. Eur J Pain. 2001; 5:391–403.
63. Lee KK. Psychopharmacological treatment for chronic pain. Korean J Psychopharmacol. 2008; 19:77–84.
XML Download